Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and CyclophosphamidePaola Papaldo, F. Calabresi, Massimo Lopez et al.|Journal of Clinical Oncology|2005Cited by 96
Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and CyclophosphamidePaola Papaldo, Paolo Marolla, Francesca Conti et al.|Journal of Clinical Oncology|2003Cited by 76
Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?Paola Papaldo, Francesco Cognetti, G. Ferretti et al.|Journal of Clinical Oncology|2006Cited by 42
Is Recurrent Venous Thromboembolism After Therapy Reduced by Low-Molecular-Weight Heparin Compared With Oral Anticoagulants?G. Ferretti, F. Cognetti, Emilio Bria et al.|CHEST Journal|2006Cited by 41
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trialsG. Ferretti, Paolo Carlini, Emilio Bria et al.|British Journal of Cancer|2006Cited by 38